Full history for every metric is available with a Kvantra account
Amyris, Inc. (AMRS)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 143 | 80 | 153 | 173 | 342 | 270 | 268 |
| Operating profit | $m | -593 | -562 | |||||
| Net profit | $m | -77 | -211 | -243 | -324 | -264 | -536 | -628 |
| EPS reported | $ | -1.58 | -1.83 | |||||
| Operating cashflow per share | $ | -1.55 | -1.55 | |||||
| Capex per share | $ | 0.31 | 0.31 | |||||
| FCF per share | $ | -1.86 | -1.86 | |||||
| Free cash flow | $m | -632 | -540 | |||||
| Net debt | $m | 917 | 930 | |||||
| Book value equity | $m | -484 | -664 | |||||
| Book value per share | $ | -1.43 | -1.82 | |||||
| Number of shares | m | 339.33 | 365.6 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.07 | -0.02 | |||||
| P/S LTM | x | 1.92 | 0.06 | |||||
| P/FCF LTM | x | -0.82 | -0.03 | |||||
| EV/EBITDA LTM | x | -2.95 | -1.90 | |||||
| EV/Sales LTM | x | 5.32 | 3.53 | |||||
| Earnings Yield LTM | % | -103.23% | -3158.7% | |||||
| FCF Yield | % | -121.70% | -3344.5% | |||||
| Quality | ||||||||
| ROE | % | 110.80% | 461.51% | |||||
| ROIC | % | -105.14% | -105.14% | |||||
| Operating margin | % | -219.63% | -219.63% | |||||
| Gross margin | % | 4.14% | 4.14% | |||||
| FCF/Sales | % | -234.15% | -234.15% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -21.06% | +20.46% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.64 | -0.52 | |||||
| Net Debt/EBITDA | x | -1.88 | -1.88 | |||||
| EBIT/Net interest | x | -23.96 | -23.96 | |||||
| Net debt/market cap | % | 176.65% | 5753.2% | |||||
| Net debt/Equity | x | -1.90 | -1.40 | |||||
| Gross debt/equity | x | -2.03 | -1.56 | |||||
Company overview
Amyris, Inc. is a synthetic biotechnology enterprise with global operations in the clean health, beauty, and flavors and fragrance sectors, covering Europe, North America, Asia, and South America. The company produces and sells a variety of consumer goods, including clean beauty, personal care, and health and wellness products, as well as specialized ingredients supplied to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care industries. Its product offerings are marketed under brand names such as Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN. Amyris also engages in a collaborative agreement with the Infectious Disease Research Institute for the advancement of a COVID-19 vaccine. Founded in 2003 and based in Emeryville, California, the company operated as Amyris Biotechnologies, Inc. until it adopted its current name, Amyris, Inc., in June 2010.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Amyris, Inc. (AMRS)
Amyris, Inc. is a synthetic biotechnology enterprise with global operations in the clean health, beauty, and flavors and fragrance sectors, covering Europe, North America, Asia, and South America. The company produces and sells a variety of consumer goods, including clean beauty, personal care, and health and wellness products, as well as specialized ingredients supplied to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care industries. Its product offerings are marketed under brand names such as Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN. Amyris also engages in a collaborative agreement with the Infectious Disease Research Institute for the advancement of a COVID-19 vaccine. Founded in 2003 and based in Emeryville, California, the company operated as Amyris Biotechnologies, Inc. until it adopted its current name, Amyris, Inc., in June 2010.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free